Baxter International Inc. brought its full and considerable weight to bear to the orthobiologics market by paying handsomely for ApaTech Ltd., a privately held start-up with a silicate substituted calcium phosphate synthetic bone graft material. [See Deal] Baxter paid $240 million up front for the right to take on Medtronic PLC, Orthovita Inc. and other companies selling bone graft materials to the spinal market. Ultimately, Baxter will likely pay more than five times the company's 2009 revenue of $60 million, having agreed to kick in an additional $90 million if the bone graft products hit sales milestones.
Baxter Spends Big on ApaTech to Join Orthobiologics Fray
Baxter International Inc. brought its full and considerable weight to bear to the orthobiologics market by paying handsomely for Apatech Inc., a privately held start-up with a silicate substituted calcium phosphate synthetic bone graft material.
More from Archive
More from In Vivo
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
• By
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.